Dual designations support development of a potential first disease-modifying therapy for an ultra-rare neurometabolic disorder BOSTON, Aug. 5, 2026 /PRNewswire/ -- Galibra Neuroscience announced a significant regulatory milestone with the receipt of both Orphan Drug Designation (ODD) and...
Hence then, the article about galibra neuroscience receives fda orphan drug and rare pediatric disease designations for ssadh deficiency gene therapy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Galibra Neuroscience Receives FDA Orphan Drug and Rare Pediatric Disease Designations for SSADH Deficiency Gene Therapy )
Also on site :
- Ted Lasso: Jason Sudeikis & Co. Break Down Season 4 Premiere — Plus, Why [Spoiler] Drives Ted's Big Decision
- Phil Collins Discusses Darkest Darks of Life-Threatening Health Struggles: 'People Were Coming to Say Goodbye'
- Weezer Announce Dates For 2026-2027 International The Gathering Tour, Drop Star-Studded ‘C.E.O.’ Video